Try For Free 7-Day Free Trial
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
|Overall||1 of 1|
|Sector (Life Science)||1 of 1|
|Type (Add-on Acquisition)||1 of 1|
|Country (Netherlands)||1 of 1|
|Year (1999)||1 of 1|